AlphaFold Found Possible Psychedelics

Original Article ↗ Hacker News Discussion ↗

AlphaFold’s ability to predict 3D structures of hard-to-study proteins, especially GPCRs, is raising hopes that AI can vastly accelerate drug discovery, including safer or more selective psychedelics targeting serotonin receptors. Commenters debate how much of this represents a true breakthrough versus better “first guesses” for traditional tools, and note that real-world impact still depends on biology’s complexity, regulation, and clinical validation. Alongside optimism about Nobel-level significance, there are concerns about misuse of novel compounds as research chemicals, as well as broader reflections on the evolutionary role of psychedelics and the societal consequences of increasingly powerful AI in biomedicine.

AlphaFold, GPCRs, and Drug Discovery

  • Several commenters highlight that the big deal isn’t “new psychedelics” per se, but that AlphaFold 2 (AF2) structures appear usable for discovering ligands to GPCRs, a major drug target class.
  • If AF2 can replace many expensive protein dynamics simulations, it could greatly cut cost and time in early-stage drug discovery.
  • Some speculate AF2-level work is Nobel-worthy and see this as one of the most important biomedical advances in decades.

Skepticism About Screening and AF2

  • Others argue virtual screening tools may be relatively insensitive to model quality, so hit rates might not prove AF2 is capturing real dynamics.
  • They note that large enough virtual screens will usually find some binders, and many tight binders still fail as useful drugs.
  • Overall sentiment: promising, but might be “just” one bottleneck eased rather than a full revolution.

GPCR Biology and Potential Uses

  • GPCRs are framed as a cellular “switchboard” for signal transduction, affecting many physiological systems.
  • Existing drugs targeting GPCRs cover a large fraction of current therapeutics; better structural models could enable more selective ligands (e.g., across serotonin receptor subtypes) and finer control of physiology.

Psychedelics, Research Chemicals, and Legal Context

  • Multiple comments predict AF2-designed psychedelics will become “research chemicals,” with concerns about mislabeling, contamination, and severe adverse events (e.g., historical Bromo-DragonFLY cases).
  • Some argue legalization of established drugs would greatly reduce risky RC experimentation; a minority identify as careful “true psychonauts.”
  • There is interest in whether AI will help generate individualized psychoactive or cognitive-enhancing drugs.

Safety and Risk Debates

  • Psychedelics like LSD are described by some as “pretty safe,” especially compared with many legal drugs; others point to rare but serious outcomes (e.g., persistent visual or psychiatric disturbances) and insist risks not be minimized.
  • Autoimmune disease is mentioned as a “final boss” where similar AI-driven approaches might someday help, but no concrete pathway is discussed.

Protein Folding and AI Limits

  • One comment gives an intuitive magnet-and-string analogy to convey how complex real protein folding and membrane embedding are, emphasizing AF2 as a strong starting point, not a full solution.
  • Some express broader skepticism, comparing AF2 to code LLMs and asking how much has been experimentally validated; others reply that, even if imperfect, AF2 structures already accelerate many projects.